(NASDAQ:CRDF), SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) — Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that clinical data from an investigator-sponsored trial with onvansertib in chronic myelomonocytic leukemia (CMML) will be presented in a poster presentation at the […]

(NASDAQ:ASMB), – 98% reduction in HSV-2 shedding rate, >99% reduction in high viral load shedding rate and 91% reduction in virologically confirmed genital lesion rate observed in 50 mg weekly oral dose of ABI-1179, exceeding expectations for the study – – 76% reduction in HSV-2 shedding rate, 81% reduction in high viral load shedding rate

(NASDAQ:MAMA), Revenues Grow 50% YoY to $47.3 Million, Driven by Double-Digit Organic Sales Momentum and Integration of Crown 1 Asset Acquisition EAST RUTHERFORD, NJ, Dec. 08, 2025 (GLOBE NEWSWIRE) — Mama's Creations, Inc. (Nasdaq: MAMA), a leading national marketer and manufacturer of fresh deli prepared foods, has reported its financial results for the third quarter

Oil-Dri Announces Second Highest Quarterly Earnings in History GlobeNewswire December 08, 2025 CHICAGO, Dec. 08, 2025 (GLOBE NEWSWIRE) — Oil-Dri Corporation of America (NYSE: ODC), producer and marketer of sorbent mineral products, today announced results for its first quarter of fiscal year 2026. First Quarter (in thousands, except per share amounts) Ended October 31, 2025

Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of Hematology (ASH) Annual Meeting 2025 GlobeNewswire December 08, 2025 Data show deep, durable responses in the 50 million cell dose level cohort; initial data suggest substantial early improvement in three patients dosed

Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025 GlobeNewswire December 08, 2025 SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) — Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that clinical data

Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in Recurrent Genital Herpes GlobeNewswire December 08, 2025 – 98% reduction in HSV-2 shedding rate, >99% reduction in high viral load shedding rate and

Mama's Creations Reports Third Quarter Fiscal 2026 Financial Results GlobeNewswire December 08, 2025 Revenues Grow 50% YoY to $47.3 Million, Driven by Double-Digit Organic Sales Momentum and Integration of Crown 1 Asset Acquisition EAST RUTHERFORD, NJ, Dec. 08, 2025 (GLOBE NEWSWIRE) — Mama's Creations, Inc. (Nasdaq: MAMA), a leading national marketer and manufacturer of fresh

Protara Announces Closing of $75 Million Public Offering GlobeNewswire December 08, 2025 NEW YORK, Dec. 08, 2025 (GLOBE NEWSWIRE) — Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the closing of its underwritten public offering of 13,043,479 shares of its common

Reed's, Inc. Announces Closing of $10 Million Public Offering and Uplisting to NYSE American Stock Exchange GlobeNewswire December 08, 2025 NORWALK, Conn., Dec. 08, 2025 (GLOBE NEWSWIRE) — Reed's, Inc. (NYSE American: REED) (“Reed's” or the “Company”), owner of the nation's leading portfolio of handcrafted, natural ginger beverages, today announced the closing of its previously